ORBEL_HEALTH_LIMITED - Accounts


Company Registration No. 06746041 (England and Wales)
ORBEL HEALTH LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2018
PAGES FOR FILING WITH REGISTRAR
ORBEL HEALTH LIMITED
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 7
ORBEL HEALTH LIMITED
BALANCE SHEET
AS AT
31 DECEMBER 2018
31 December 2018
- 1 -
2018
2017
Notes
£
£
£
£
Fixed assets
Intangible assets
3
145,468
157,958
Tangible assets
4
752
9,437
146,220
167,395
Current assets
Stocks
6,210
27,483
Debtors
5
99,084
62,507
Cash at bank and in hand
15,151
9,280
120,445
99,270
Creditors: amounts falling due within one year
6
(109,740)
(33,181)
Net current assets
10,705
66,089
Total assets less current liabilities
156,925
233,484
Creditors: amounts falling due after more than one year
7
(45,766)
(46,223)
Provisions for liabilities
(143)
(1,793)
Net assets
111,016
185,468
Capital and reserves
Called up share capital
8
136,518
86,556
Share premium account
1,392,721
1,392,721
Profit and loss reserves
(1,418,223)
(1,293,809)
Total equity
111,016
185,468

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 31 December 2018 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

ORBEL HEALTH LIMITED
BALANCE SHEET (CONTINUED)
AS AT
31 DECEMBER 2018
31 December 2018
- 2 -
The financial statements were approved by the board of directors and authorised for issue on 23 July 2019 and are signed on its behalf by:
A P Fehon
Director
Company Registration No. 06746041
ORBEL HEALTH LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2018
- 3 -
1
Accounting policies
Company information

Orbel Health Limited is a private company limited by shares incorporated in England and Wales. The registered office is 82 St John Street, London, EC1M 4JN.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Going concern

The directors have a reasonable expectation that the company will continue to have adequate resources to remain in operational existence for the foreseeable future, for more than one year from date of approval of these accounts. As such the going concern assumption has been applied in preparing the financial statement. Further to this, continued support will be available from the shareholders for the foreseeable future.

1.3
Turnover

Turnover represents the amounts derived from sales of goods which fall within the company's principal activity, stated net of value added tax. The company recognises turnover when the goods are dispatched.

1.4
Research and development expenditure

Research expenditure is written off against profits in the year in which it is incurred. Identifiable development expenditure is capitalised to the extent that the technical, commercial and financial feasibility can be demonstrated.

1.5
Intangible fixed assets other than goodwill

Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

 

Intangible assets acquired on business combinations are recognised separately from goodwill at the acquisition date where it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity and the fair value of the asset can be measured reliably.

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Patents
10% on straight line basis
1.6
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

ORBEL HEALTH LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2018
1
Accounting policies
(Continued)
- 4 -

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Plant and machinery
25% on cost
Fixtures, fittings & equipment
25% on cost

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.7
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

 

Stocks held for distribution at no or nominal consideration are measured at the lower of replacement cost and cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.8
Cash at bank and in hand

Cash at bank and in hand are basic financial assets and include cash in hand and deposits held at call with banks.

1.9
Debtors

Short term debtors are measured at transaction price, less any impairments.

1.10
Creditors

Short term creditors are measured at the transaction price.

1.11
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.12
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

ORBEL HEALTH LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2018
1
Accounting policies
(Continued)
- 5 -
Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.13
Leases

Rentals payable under operating leases, including any lease incentives received, are charged to income on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the lease asset are consumed.

1.14
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation are included in the profit and loss account for the period.

2
Employees

There were no employees in the period.

3
Intangible fixed assets
Patents
£
Cost
At 1 January 2018
247,589
Additions
12,937
At 31 December 2018
260,526
Amortisation and impairment
At 1 January 2018
89,631
Amortisation charged for the year
25,427
At 31 December 2018
115,058
Carrying amount
At 31 December 2018
145,468
At 31 December 2017
157,958
ORBEL HEALTH LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2018
- 6 -
4
Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 January 2018 and 31 December 2018
84,284
Depreciation and impairment
At 1 January 2018
74,847
Depreciation charged in the year
8,685
At 31 December 2018
83,532
Carrying amount
At 31 December 2018
752
At 31 December 2017
9,437
5
Debtors
2018
2017
Amounts falling due within one year:
£
£
Other debtors
99,084
62,507
6
Creditors: amounts falling due within one year
2018
2017
£
£
Trade creditors
10,824
6,387
Other creditors
98,916
26,794
109,740
33,181
7
Creditors: amounts falling due after more than one year
2018
2017
£
£
Other creditors
45,766
46,223

Included in other creditors was an unsecured and interest free convertible loan the company received from the Royal College of Art amounting to £45,766 (2017: £46,223), which is repayable after more than one year.

ORBEL HEALTH LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2018
- 7 -
8
Called up share capital
2018
2017
£
£
Ordinary share capital
Issued and fully paid
13,651,795 Ordinary shares of 1p each
136,518
86,556
136,518
86,556

During the year the company issued 4,996,211 ordinary shares of 1p at par.

9
Related party transactions

Solway Nominees Pty Ltd

 

During the year Solway Nominees Pty Ltd, a shareholder paid expenses on behalf of the company totalling £16,841 (2017: £nil) and provided unsecured and interest free loans of £58,248 (2017: £nil).The loans are repayable on the earlier of 30 June 2019 and the company issuing any new securities. The company owed Solway Nominees Pty Ltd £75,089 (2017: £nil) at the balance sheet and this amount is included within other creditors.

10
Directors' transactions

Other creditors includes loan of £22,466 (2017: £22,466) made to the company by a former director. The loan is interest free and repayable on demand.

2018-12-312018-01-01falseCCH SoftwareCCH Accounts Production 2019.100No description of principal activity23 July 2019A SutcliffeA P FehonP J HigginsJ D Pyers2020 Secretarial Limited067460412018-01-012018-12-31067460412018-12-31067460412017-12-3106746041core:PatentsTrademarksLicencesConcessionsSimilar2018-12-3106746041core:PatentsTrademarksLicencesConcessionsSimilar2017-12-3106746041core:OtherPropertyPlantEquipment2018-12-3106746041core:OtherPropertyPlantEquipment2017-12-3106746041core:CurrentFinancialInstruments2018-12-3106746041core:CurrentFinancialInstruments2017-12-3106746041core:Non-currentFinancialInstruments2018-12-3106746041core:Non-currentFinancialInstruments2017-12-3106746041core:ShareCapital2018-12-3106746041core:ShareCapital2017-12-3106746041core:SharePremium2018-12-3106746041core:SharePremium2017-12-3106746041core:RetainedEarningsAccumulatedLosses2018-12-3106746041core:RetainedEarningsAccumulatedLosses2017-12-3106746041core:ShareCapitalOrdinaryShares2018-12-3106746041core:ShareCapitalOrdinaryShares2017-12-3106746041bus:Director22018-01-012018-12-3106746041core:PlantMachinery2018-01-012018-12-3106746041core:FurnitureFittings2018-01-012018-12-3106746041core:PatentsTrademarksLicencesConcessionsSimilar2017-12-3106746041core:PatentsTrademarksLicencesConcessionsSimilarcore:ExternallyAcquiredIntangibleAssets2018-01-012018-12-3106746041core:PatentsTrademarksLicencesConcessionsSimilar2018-01-012018-12-3106746041core:OtherPropertyPlantEquipment2017-12-3106746041core:OtherPropertyPlantEquipment2018-01-012018-12-3106746041bus:OrdinaryShareClass12018-12-3106746041bus:OrdinaryShareClass12018-01-012018-12-3106746041bus:PrivateLimitedCompanyLtd2018-01-012018-12-3106746041bus:FRS1022018-01-012018-12-3106746041bus:AuditExemptWithAccountantsReport2018-01-012018-12-3106746041bus:SmallCompaniesRegimeForAccounts2018-01-012018-12-3106746041bus:Director12018-01-012018-12-3106746041bus:Director32018-01-012018-12-3106746041bus:Director42018-01-012018-12-3106746041bus:CompanySecretary12018-01-012018-12-3106746041bus:FullAccounts2018-01-012018-12-31xbrli:purexbrli:sharesiso4217:GBP